Cargando…
Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador
Neuroendocrine tumors (NETs) represent a heterogeneous malignancy group of neoplasms, with a limited amount of data from Latin America. Thus, this observational study aimed to provide data about the prevalence, incidence, and survival rates for NET in Ecuadorian hospitals. The study was conducted us...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408119/ https://www.ncbi.nlm.nih.gov/pubmed/36011226 http://dx.doi.org/10.3390/healthcare10081569 |
_version_ | 1784774529279590400 |
---|---|
author | Escobar, Karime Montes Vicente-Villardon, Jose Luis Villacís Gonzalez, Rosa Elisa Castillo Cordova, Paul Humberto Sánchez Rodríguez, Johanna Mabel De la Cruz-Velez, Melina Siteneski, Aline |
author_facet | Escobar, Karime Montes Vicente-Villardon, Jose Luis Villacís Gonzalez, Rosa Elisa Castillo Cordova, Paul Humberto Sánchez Rodríguez, Johanna Mabel De la Cruz-Velez, Melina Siteneski, Aline |
author_sort | Escobar, Karime Montes |
collection | PubMed |
description | Neuroendocrine tumors (NETs) represent a heterogeneous malignancy group of neoplasms, with a limited amount of data from Latin America. Thus, this observational study aimed to provide data about the prevalence, incidence, and survival rates for NET in Ecuadorian hospitals. The study was conducted using data from the Society for the Fight Against Cancer (SOLCA). We evaluated patients with NETs (2000–2020) using the HJ-Biplot method and Cox proportional hazards. Annual age-adjusted incidence and limited-duration prevalence in multivariable analyses as well as hazard ratios (HRs) for mortality and survival were obtained. In the years 2000–2020, the age-adjusted incidence rate increased by 9-fold in the stomach and by 7-fold in the breast. The incidence rates were 1.38 per 100,000 persons in the lung and at 1.79 per 100,000 persons in gastroenteropancreatic sites (rectum, stomach, and pancreas). The prevalence increased from 0.0027% in 2000 to 0.0736% in 2019 and 0.0245% in 2020. Overall survival was worse for metastatic NETs (HR, 4.061; 95% CI, 1.932–8.540; p < 0.001) and advanced local NETs (HR, 2.348; 95% CI, 1.007–5.475 p < 0.048) than for localized NETs. In conclusion, the NET incidence increased in the last 20 years and survival decreased over time, especially for metastatic tumors in the pancreas and the nostril. |
format | Online Article Text |
id | pubmed-9408119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94081192022-08-26 Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador Escobar, Karime Montes Vicente-Villardon, Jose Luis Villacís Gonzalez, Rosa Elisa Castillo Cordova, Paul Humberto Sánchez Rodríguez, Johanna Mabel De la Cruz-Velez, Melina Siteneski, Aline Healthcare (Basel) Article Neuroendocrine tumors (NETs) represent a heterogeneous malignancy group of neoplasms, with a limited amount of data from Latin America. Thus, this observational study aimed to provide data about the prevalence, incidence, and survival rates for NET in Ecuadorian hospitals. The study was conducted using data from the Society for the Fight Against Cancer (SOLCA). We evaluated patients with NETs (2000–2020) using the HJ-Biplot method and Cox proportional hazards. Annual age-adjusted incidence and limited-duration prevalence in multivariable analyses as well as hazard ratios (HRs) for mortality and survival were obtained. In the years 2000–2020, the age-adjusted incidence rate increased by 9-fold in the stomach and by 7-fold in the breast. The incidence rates were 1.38 per 100,000 persons in the lung and at 1.79 per 100,000 persons in gastroenteropancreatic sites (rectum, stomach, and pancreas). The prevalence increased from 0.0027% in 2000 to 0.0736% in 2019 and 0.0245% in 2020. Overall survival was worse for metastatic NETs (HR, 4.061; 95% CI, 1.932–8.540; p < 0.001) and advanced local NETs (HR, 2.348; 95% CI, 1.007–5.475 p < 0.048) than for localized NETs. In conclusion, the NET incidence increased in the last 20 years and survival decreased over time, especially for metastatic tumors in the pancreas and the nostril. MDPI 2022-08-18 /pmc/articles/PMC9408119/ /pubmed/36011226 http://dx.doi.org/10.3390/healthcare10081569 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Escobar, Karime Montes Vicente-Villardon, Jose Luis Villacís Gonzalez, Rosa Elisa Castillo Cordova, Paul Humberto Sánchez Rodríguez, Johanna Mabel De la Cruz-Velez, Melina Siteneski, Aline Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador |
title | Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador |
title_full | Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador |
title_fullStr | Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador |
title_full_unstemmed | Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador |
title_short | Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador |
title_sort | neuroendocrine tumors: an analysis of prevalence, incidence, and survival in a hospital-based study in ecuador |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408119/ https://www.ncbi.nlm.nih.gov/pubmed/36011226 http://dx.doi.org/10.3390/healthcare10081569 |
work_keys_str_mv | AT escobarkarimemontes neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador AT vicentevillardonjoseluis neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador AT villacisgonzalezrosaelisa neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador AT castillocordovapaulhumberto neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador AT sanchezrodriguezjohannamabel neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador AT delacruzvelezmelina neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador AT siteneskialine neuroendocrinetumorsananalysisofprevalenceincidenceandsurvivalinahospitalbasedstudyinecuador |